NEW YORK (GenomeWeb News) – Promega and ATCC today announced a collaboration for cell banking and bioproduction of cells in order to create bioluminescence-based drug discovery assays for biologics.
The deal calls for ATCC to produce and authenticate cell banks and production lots of engineered and stock cell lines for use as cellular reagents as Promega creates a line of new cell-based assay systems for biologics. The initial system will be for biologics drug discovery.
The first product offering from the partnership will be an antibody-dependent cell-mediated cytotoxicity reporter assay from Promega, to be launched sometime this year. This and other reporter assays to be developed will provide reduced variability to bioassays for biologics, Promega said in a statement.
The ADCC and other bioassay systems are currently in alpha and beta testing programs for qualification by biologic drug manufacturers.
Financial and other details of the deal were not disclosed.